The phase 3 trial assessed Xtandi plus androgen deprivation therapy (ADT) against placebo plus ADT in men with non-metastatic castration-resistant prostate cancer (nmCRPC). The OS was a major
This eight-week trial randomized 402 adult patients equally at more than 45 centers in the United States. In this trial, troriluzole monotherapy at 100mg twice daily did not differentiate
The designation has been granted for the investigation of NBTXR3 activated by radiation therapy, with or without cetuximab, to treat patients with locally advanced head and neck squamous
The transaction contemplates the retention of nearly the entirety of the Valeritas workforce. To accomplish the sale in the most efficient manner, Valeritas and its subsidiaries filed voluntary
The gantenerumab arm of phase II/III DIAN-TU-001 study has failed to meet its primary endpoint in people who have an early-onset, inherited form of AD or otherwise known
“There is an urgent need for new therapeutic options to treat hypoxic-ischemic encephalopathy, a devastating condition that profoundly impacts newborns and their families,” said Ulrich Thienel, M.D., Ph.D.,
Based in Baarn, Covis is involved in the marketing and distribution of branded pharma products for the treatment of chronic and serious medical issues. The company supplies products
On January 14, 2020, the Company received U.S Food and Drug Administration (FDA) Fast Track Designation for its Oncoprex immunogene therapy in combination with the EGFR tyrosine kinase
Under an exclusive worldwide licence, Aimmune will develop and commercialise the XmAb 7195, an investigational humanised monoclonal antibody. Xencor president and CEO Dr Bassil Dahiyat said: “Aimmune’s focus,
The expansion of the study to the US builds upon Immix’ results from Australia, wherein six cohorts were dosed with no treatment-related serious adverse events observed and dose
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.